Key clinical point: CPX-351 therapy was tied to long-term remission and survival in older patients with newly diagnosed high-risk or secondary AML.
Major finding: Remission (CR or CRi) was achieved by 48% of patients in the CPX-351 arm and 33% of patients in the 7+3 arm.
Study details: Five-year results of phase 3 comparison of CPX-351 vs. 7+3 regimen of cytarabine and daunorubicin in more than 300 older adult patients with newly diagnosed high-risk or secondary AML.
Disclosures: The study was funded by Jazz Pharmaceuticals. Dr. Lancet disclosed that he has a consulting or advisory role for Agios, Daiichi Sankyo, Jazz Pharmaceuticals, and Pfizer.
Lancet JE et al. ASCO 2020, Abstract 7510.